A report posted yesterday on the ABC Foreign Correspondent web site indicates the potential huge market for VitroGro "down the track" given the surging incidence of diabetes in the developing world. The full report can be found at:
Here's just a few paragraphs to highlight the problem (and the potential opportunity for Tissue Therapies and its cost-effective VitroGro product used to treat diabetic leg and foot ulcers, as well as other wounds):
"India is bracing for a massive surge in type 2 diabetes, with credible estimates putting the number of sufferers in the next 20 years at more than 100 million."
".... Between them, India and China now have more than half of the world's type 2 diabetics."
"..Compared to Europeans, Indians get diabetes at a much younger age....the late 30's or early 40's, as opposed to early 50's in the Europeans".
"..What makes it worse is that many Indians suffering from type 2 diabetes are unaware they have it, which means that by the time they seek treatment, it is often too late to avoid limb amputation (and loss of sight)."
"It is a frightening phenomenon that threatens to overwhelm the country's health system, according to a leading diabetes specialist in India."
Regards,
Goggo
TIS Price at posting:
48.0¢ Sentiment: LT Buy Disclosure: Held
